RAD — Radiopharm Theranostics Share News
0.000.00%
Last trade - 00:00- AU$70.88m
- AU$34.53m
- AU$3.63m
Brief: Radiopharm Theranostics Seeks Trading Halt
Brief: Radiopharm Theranostics Says HY Loss A$24.8 Million Versus Loss A$12.6 Million
Brief: Radiopharm Theranostics Secures Share Facility Agreement Of Up To A$12.5M
Brief: Radiopharm Theranostics Announces Entitlement Offer To Raise Around A$10 Mln
Australia's Radiopharm Theranostics hits 2-month low on discounted raise
Brief: Radiopharm Theranostics Says FDA Accepted Amended IND For Production And Distribution Of 68Ga-Trivehexin
Brief: Rad Receives Approval For Phase 1 Therapeutic Study Of Pdl1-Nanobody In Non-Small Cell Lung Cancer
Brief: Radiopharm Theranostics Says FY Net Loss Attributable A$34.6 Mln
Brief: Radiopharm Theranostics Announce Expanded Agreement With Terthera To Supply Terbium-161
Brief: Radiopharm Theranostics Says Positive Guidance From FDA Pre-IND Meeting
Brief: Radiopharm Theranostics Receives FDA Orphan Drug Designation For Trivehexin (Rad 301) In Pancreatic Cancer
Brief: Radiopharm Theranostics Says U.S. FDA Granted Orphan Drug Designation To GA68-TRIVEHEXIN
Australia's Radiopharm Theranostics rises on supply agreement with Dutch firm
Brief: Radiopharm Theranostics Says It Enters Supply Agreement With TerThera
Brief: Radiopharm Theranostics Says Via Unit Entered Binding Agreement To Acquire Pharma15 Corp
Brief: Radiopharm Theranostics Posts HY Net Loss Attributable A$12.6 Million
Brief: Radiopharm Theranostics Initiates Process For Nasdaq Listing
Brief: Radiopharm Theranostics Initiates Process For Nasdaq Listing
Australia's Radiopharm Theranostics jumps on receiving U.S. FDA approval